|Bid||0.010 x 100|
|Ask||1.900 x 500|
|Day's Range||1.711 - 1.855|
|52 Week Range||0.800 - 3.165|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.00|
Oasmia Pharmaceutical AB (publ) (“Oasmia” or the “Company”) hereby announces that the Company has completed a private placement of a convertible loan in the amount of SEK 26,000,000 with an interest rate of 8 per cent per year directed to and placed with a limited group of investors and paid in cash (the “Private Placement”). The convertible instrument issue is expected to provide the Company with SEK 26,000,000 before transaction related costs.
Oasmia Pharmaceutical AB announces that all patients have been treated in the two ongoing studies with Docecal in metastatic breast cancer.. Uppsala, Sweden, February 19, 2018– Oasmia Pharmaceutical AB, ...
Categories: Yahoo FinanceGet free summary analysis Oasmia Pharmaceutical AB reports financial results for the quarter ended July 31, 2017. We analyze the earnings along side the following peers of Oasmia Pharmaceutical AB – OncoMed Pharmaceuticals, Inc., Omeros Corporation and Ohr Pharmaceutical, Inc. (OMED-US, OMER-US and OHRP-US) that have also reported for this period. Highlights Summary numbers: Revenues ... Read more (Read more...)
Categories: Yahoo FinanceGet free summary analysis Oasmia Pharmaceutical AB reports financial results for the quarter ended April 30, 2017. Highlights Summary numbers: Revenues of USD 0.00 million, Net Earnings of USD -4.71 million. Gross margins narrowed from -51,783.05% to -85,334.09% compared to the same period last year, operating (EBITDA) margins now -82,834.09% from -49,876.27%. Change in operating ... Read more (Read more...)